for full article see link here :
“On Seroxat I lost all emotion, I couldn’t feel anything and I didn’t care about anyone, least of all myself. I had never had depression before but this anti-depressant made me feel suicidal. I started drinking heavily and I tried to kill myself a few times.”
In a 2010 article in the Huffington Post, MIA Blogger Peter Breggin lamented that the FAA had recently lifted its absolute ban on antidepressants and was instead providing a “Medication Guide to patients and their families that warns about dangerous drug-induced reactions including suicide, violence and a variety of unexpected negative behaviors.” Breggin warned that, “The FAA should reverse its ruling before it’s too late and hundreds of lives are lost when a pilot becomes impulsive, suicidal or violent–or just loses his sharpness–under the influence of antidepressant medication.”
I have been drawing attention to the dangers of SSRI medications for over 8 years now on this blog, and since that time I have also drawn attention towards the various cases, of SSRI induced violence, including suicide, homicide, and murder/suicide. I was on Seroxat (Paxil/SSRI) for 4 years, I was never aggressive until I started to take it. I experienced suicidal thoughts, homicidal thoughts, increased hostility, irritability, and numerous other side effects which were all caused directly by Seroxat. Many other SSRI’s and psychiatric drugs have the same effects. They even warn on the packets that they have these effects. Murder/suicides, and in particular, mass- murder suicides have been linked to SSRI/anti-depressant/psychiatric drug use, and withdrawal for decades now. I have spoken to dozens of people who have had these effects, there are literally tens of thousands of online forums where people are expressing their horror stories of SSRI’s and psychiatric drugs, many of these horror stories include behavioral changes, major mood swings, impulsiveness, violent thoughts and actions, etc etc. These are all side effects of SSRI’s, they are well documented. These are not conspiracy theories- these are facts.
Andreas Lubitz, killed himself, and hundreds of plane passengers, while under the ‘care’ of the psychiatric profession. There has been much speculation today in the media about what drugs was he prescribed, how bad was his depression, how long did he have it etc etc but very little attention has been put on the side effects of the drugs he might have been on, the dangers in withdrawal (where the effects are horrendous) and the fact that these drugs are ‘mind-altering’ (the clue is in the word- ‘mind-altering’).
In one article, high-profile psychiatrist, Simon Wessely has been warning of the dangers of a knee-jerk reaction to this case. He says that we should not stop depressed pilots from flying because this is ‘an utterly bizarre and unpredictable event’…
“What does cause trouble is saying that if you ever have a history of depression then you should not be allowed to do whatever. That is wrong, as much as saying that people with a history of broken arms shouldn’t be allowed to do something.’
“Prof Wessely also stressed there was not a link between depression and aggressive suicide.”
Furthermore, the piece says, “around 100 commercial pilots in the UK have a history of depression with 42 currently on medication”.
Treatment may not have precipitated what happened in this case but there are many people in the pharmaceutical industry who have known for a long time that something like this can happen on their medication and they have done nothing to put in place systems to manage these risks or to dismantle the system that gives rise to risks like this at a much greater rate than we should have to tolerate.
That corporations might do this is not a conspiracy theory. In the famous Ford Pinto case, a Ford executive made aware of risks that their car would lead to a regular number of drivers and passengers being incinerated each year – a problem that could have been inexpensively put right – famously wrote
The powers that be have been winging it for decades.
Is Zofran Manufacturer GSK Talking from Both Sides of Its Mouth?
|March 27, 2015, 08:00:00AM. By Gordon Gibb|
Pittsburgh, PA: Twenty-three years is a long time. And yet, that’s the timespan a Zofran lawsuit alleges that Zofran manufacturer GlaxoSmithKline (GSK) has been in possession of evidence suggesting a risk of birth defects associated with the use of Zofran in pregnancy.
Various studies have offered conflicting views on Zofran, and other generic versions of ondansetron (Zofran). And there is little doubt about ondansetron’s capacity for curbing nausea – an often debilitating byproduct of pregnancy. For some women, morning sickness can be so extreme that only medication can prevent the sometimes constant vomiting, dehydration and weight loss that severe morning sickness can foster.
And yet, ondansetron was never approved by the US Food and Drug Administration (FDA) for use as a treatment for morning sickness. Zofran manufacturer GSK makes that very point, noting in a Canadian media report last June that “the safety of ondansetron for use in human pregnancy has not been established…[GSK] monitors and reports all adverse event reports…” (The Toronto Star, 6/25/14).
But is GSK talking from both sides of its mouth? That’s the way it appears, as GSK was previously accused of promoting Zofran off-label for morning sickness, or so it is alleged. The US Department of Justice asserted that GSK had not only promoted Zofran and other drugs off-label, but that the company provided kickbacks to doctors in exchange for prescribing Zofran for morning sickness. Court documents, according to The Toronto Star, alleged that GSK disseminated false and misleading information about the safety and effectiveness of Zofran.
In 2012, GSK settled with the US Department of Justice for $3 billion. As part of the settlement, GSK was not required to admit to any wrongdoing. That latter bit is a frequent feature of government settlements: the ability to escape a finding of wrongdoing in exchange for a massive payment.
One of the more recent Zofran lawsuits, filed by plaintiff Cheri Flynn in Pennsylvania, mirrors allegations contained in the US Department of Justice lawsuit: that GSK knowingly marketed Zofran to pregnant women without sharing information about the potential for Zofran birth defects – information the lawsuit alleges GSK has had in its possession since 1992, if not before.
“GSK not only concealed this knowledge from healthcare providers and consumers in the United States, and failed to warn of the risk of birth defects,” the Flynn lawsuit states, “but GSK also illegally and fraudulently promoted Zofran to physicians and patients specifically for the treatment of morning sickness in [pregnant] women.”
READ MORE ZOFRAN BIRTH DEFECT LEGAL NEWS
Drug manufacturers do not have the legal, ethical or medical authority to market a drug off-label. Ondansetron was originally approved by the FDA for treatment of nausea in cancer patients following chemotherapy. It was never indicated for pregnant women, although doctors have always had the authority to prescribe off-label should they feel it would benefit the patient. And yet, The Toronto Star last June suggested that doctors in Canada are prescribing ondansetron off-label without having all the facts.
One wonders if the same thing is happening in the US.
“Women ingested the drug because they innocently believed that Zofran was an appropriate drug for use in their circumstance,” the Flynn lawsuit contends. “When they ingested the drug, these pregnant women had no way of knowing that Zofran had never been studied in pregnant women, much less shown to be a safe and effective treatment for pregnancy-related nausea.”
The Zofran lawsuit is Cheri Flynn v. GlaxoSmithKline LLC, Case No. 2:15-cv-00709-PD, United States District Court of the Eastern District of Pennsylvania. The lawsuit alleges that Flynn’s two children suffered congenital heart defects and other birth defects following fetal exposure to Zofran.
Zofran Lawsuit Alleges GSK Failed to Disclose Zofran Dangers
Posted: Mar 06, 2015 8:06 AM GMT
This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
Zofran lawyers at the Onder Law Firm have expanded their website to provide information about the allegations made in a new Zofran lawsuit filed in Pennsylvania.
St. Louis, MO (PRWEB) March 06, 2015
A new Zofran lawsuit has been filed in U.S. District Court in Pennsylvania, according to attorneys handling Zofran lawsuit claims alleging birth defects.* The lawsuit alleges that the plaintiffs two children suffered congenital heart defects and other birth defects after fetal exposure to Zofran, according to court documents.
This Zofran lawsuit alleges that the defendant, pharmaceutical company GlaxoSmithKline (GSK) was aware of evidence supporting a link between Zofran use during pregnancy and the increased incidence of congenital heart defects and other birth defects, according to court documents:
Since at least 1992, GSK has had mounting evidence showing that Zofran presents an unreasonable risk of harm to babies who are exposed to the drug during pregnancy.* According to court documents, the lawsuit cites numerous pieces of evidence in support of this statement, saying GSK was aware of the following:
- Zofran readily crosses human placental barriers during pregnancy.*
- Animal studies conducted on Zofran indicate that Zofran cannot be used safely or effectively in pregnant women.*
- Since 1992, GSK has received hundreds of reports of major birth defects associated with prenatal Zofran exposure.*
According to court documents, the plaintiff alleges that GSK knowingly marketed Zofran to pregnant women, without issuing a birth defects warning, despite evidence suggesting this was not a safe application of the drug: GSK not only concealed this knowledge from healthcare providers and consumers in the United States, and failed to warn of the risk of birth defects, but GSK also illegally and fraudulently promoted Zofran to physicians and patients specifically for the treatment of morning sickness in pregnancy women.*
The FDA has never approved Zofran as safe for pregnant women, yet women are still being prescribed Zofran during pregnancy, believing the drug is safe, according to court documents: “Women ingested the drug because they innocently believed that Zofran was an appropriate drug for use in their circumstance. When they ingested the drug, these pregnant women had no way of knowing that Zofran had never been studied in pregnant women, much less shown to be a safe and effective treatment for pregnancy-related nausea.”*
A few women have now stepped forward to file Zofran lawsuits. As more families learn about the allegations of birth defects from Zofran, we anticipate hearing from others interested in filing Zofran lawsuits, said Jim Onder of the Onder Law Firm.
The Onder Law Firm, nationally-renowned as a leading family safety and consumer liability law firm, provides legal representation for families seeking to file Zofran lawsuits for allegations of birth defects. Zofran attorneys representing clients nationwide offer Zofran lawsuit news and updates at their website. The firm provides no-cost, no-obligation case evaluation for mothers and families whose babies wer born with a birth defect following prenatal exposure to Zofran. Individuals who fit this description may contact a lawyer to discuss whether they have grounds for a Zofran lawsuit. The firms Zofran lawyers believe persons who meet this description may be entitled to real compensation. For more information, visit the Zofran lawsuit website.
The Onder Law Firm welcomes Zofran case inquiries from law firms in regards to handling them or working as co-counsel.
About The Onder Law Firm
Onder, Shelton, OLeary & Peterson, LLC is a St. Louis based personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The pharmaceutical and medical device litigators at The Onder Law Firm have represented thousands of Americans in lawsuits against multinational conglomerates from products liability for manufacture of defective or dangerous products to deceptive advertising practices. Other firms throughout the nation often seek its experience and expertise on complex litigation. It is also a recognized leader in products liability cases such as window blind cord strangulation. The Onder Law Firm offers information on Zofran lawsuits at http://www.247LawsuitNews.com.
*Cheri Flynn vs. GlaxoSmithKline LLC, Case 2:15-cv-00709-PD, United States District Court of the Eastern District of Pennsylvania
For the original version on PRWeb visit: http://www.prweb.com/releases/zofran-birth-defects/zofran-lawsuit/prweb12564236.htm
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
The revelation of the possible trouble with his eyes added a new element to the emerging portrait of the 27-year-old German pilot, who the authorities say was also being treated for psychological issues and had hidden aspects of his medical condition from his employer. The police found antidepressants during a search of his apartment here on Thursday, an official said Saturday.
“Germanwings co-pilot Andreas Lubitz who purposefully crashed Flight 9525 into the French Alps, killing all 150 people on board had spent 18 months overall under psychiatric treatment, Bild reported on Friday, citing anonymous sources within Lufthansa, Germanwings’ parent company. The pilot was diagnosed with a ‘severe depressive episode’ in 2009.”
By CCHR International – March 27, 2015
Numerous reports are now surfacing that Germanwings co-pilot Andreas Lubitz who purposefully crashed Flight 9525 into the French Alps, killing all 150 people on board, had in fact been under psychiatric care. What media are not reporting is the fact that Lubitz, in all likelihood was under the influence of antidepressants, drugs documented to cause depersonalization, mania, psychosis, and even homicidal ideation, considering he spent more than 18 months undergoing “psychiatric care.” Moreover, Lubitz would not be the first commercial pilot to purposefully crash a plane while under the influence of psychotropic drugs— In 2010, the National Transportation Safety Board (NTSB), issued a report on the probable cause of a 2008 plane crash in Mount Airy that killed everyone on board, showing that toxicology tests revealed the pilot had the antidepressant Zoloft in his system. The NTSB report stated, “Officials say the pilot ‘displayed non-professional behavior’ and that a cockpit voice recording documented the pilot singing, ‘Save my life, I’m going down for the last time’” shortly before crashing the plane.
The emerging facts regarding Lubitz’ psychiatric treatment:
Russia Today (RT) reports, “Lubitz had spent 18 months overall under psychiatric treatment, Bild (a German newspaper) reported on Friday, citing anonymous sources within Lufthansa, Germanwings’ parent company. The pilot was diagnosed with a ‘severe depressive episode’ in 2009.”
According to Reuters, “The pilot who appears to have deliberately crashed a plane carrying 149 others into the French Alps received psychiatric treatment for a ‘serious depressive episode’ …. Citing internal documents and Lufthansa sources, Bild said Lubitz spent a total of one and a half years in psychiatric treatment.”
The Guardian reports, “Investigators searching the Düsseldorf apartment of the co-pilot on the Germanwings flight that crashed into the French Alps on Tuesday have found evidence he hid an illness from his employers, prosecutors said on Friday. The evidence is a torn-up doctors’ note, signing him off work on the day of the crash. ‘Medical documents were found that indicate an ongoing illness and suitable medical treatment,’ Düsseldorf prosecutors said in a statement.”
Mirror states that, “Killer co-pilot Andreas Lubitz was treated in hospital just two weeks before the plane crash which killed 150 people. The 27-year-old attended a clinic at the University of Dusseldorf Hospital in February and March. The most recent visit was March 10, exactly a fortnight before he guided the Germanwings Airbus A320 into its fatal descent. The hospital said Lubitz attended for ‘diagnostic evaluation’ but insisted he was not treated for depression…. They confirmed he was suffering from a serious illness which he had concealed from his employers Germanwings. One of the sick notes was reportedly signed by either a local neurologist or psychologist.”
While the drug policies of Lufthansa, the parent company of Germanwings, are unknown, in the U.S, the Federal Aviation Administration (FAA) allows the use of antidepressants among pilots, a policy instituted in 2008, This is despite the fact there have been 134 regulatory warnings from eleven countries, including the United Kingdom, Canada, Japan, Australia, New Zealand, Ireland, Russian, Italy and Germany on antidepressants causing suicidal ideation.
Given the increasing number of questionable aircraft disasters, which, on their surface, provide no rhyme or reason for a motive, one may begin to question the use of antidepressants, especially in light of a 2007 FAA report that revealed that of the 61 air crashes between 1990-2001, “the pilot’s psychological condition and/or SSRI use was reported to be the probable cause or a contributing factor in 31% (19/61) of the accidents.”
The fact is, whether Lubitz was on psychiatric drugs, or in withdrawal from them, there is enough evidence to show that the use of antidepressants or other mind-altering psychiatric drugs by commercial pilots, in the U.S. and abroad, should be banned.
However, I will likely post every 3 months or so, just to keep the blog going, and besides, GSK always seem to hit the headlines every few months with some sordid story or other about corruption, fraud, skullduggery etc… therefore there is always material to highlight, but I have scaled back on blogging, and I intend to keep it that way…
Here is some of the last few months news:
GlaxoSmithKline CEO Andrew Witty’s pay cut 46%
LONDON – The total compensation for Andrew Witty, CEO of GlaxoSmithKline P.L.C., was reduced 46 percent last year as profits of the largest U.K. drugmaker slumped.
Witty’s annual bonus was cut 51 percent to $1.41 million, while his salary climbed 2.6 percent, to $1.68 million, taking his total pay for 2014 to $6 million, according to London-based GSK’s annual report. Compensation for chief financial officer Simon Dingemans, 51, was pared to $2.85 million.
The pay cut reflects Witty’s struggle to halt a slide in U.S. market share for Advair, the company’s top-selling asthma medication, and failure to win over doctors and insurers to products designed to replace it. Shares of GSK fell 8 percent in the past year as the drugmaker was also battered by a bribery scandal in China that resulted in a $457.6 million fine.
GlaxoSmithKline PLC said it is firing about 110 employees in China for what it describes as misconduct, the latest fallout from a bribery scandal there that has dogged the U.K. drug company for more than a year.
The move comes six months after a Glaxo subsidiary in China was found guilty by a Chinese court of bribing doctors, hospitals and other nongovernment personnel and fined more than $490 million. A Glaxo spokeswoman said on Friday the misconduct leading to the dismissals dates back more than 18 months.
“Based on the findings, we have taken disciplinary action against employees whose conduct went against GSK’s values and code of conduct. We have zero tolerance for this kind of behavior,” the company said in a statement. The spokeswoman added that the drug maker has increased its monitoring of expense claims and compliance efforts in China, and also hired lawyers and consultants to review operations.
A tally of Glaxo’s total workforce in China wasn’t immediately available.
The firings come as Glaxo seeks to rebound from the long-simmering bribery scandal in China, which resulted in suspended prison sentences for five of the company’s managers, including Mark Reilly, its former top China executive.
The episode set back Glaxo’s efforts to restore its image and revamp business practices in the wake of a $3 billion settlement with U.S. authorities three years ago. The drug maker had been accused of failing to disclose clinical trial data for certain medicines and improperly marketing drugs, among other things.